Ovarian Cancer: Recent Advances in Research and Clinical Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 17786
Special Issue Editor
Special Issue Information
Epithelial ovarian carcinoma remains a lethal gynecological malignancy among women across the globe. Although this malignancy is very responsive to therapy, the late-stage disease lacks definitive curability. Modern clinical treatment methods have increased survival rates, but drug resistance and refractory disease in recurrent patients continue to challenge oncologists. Translational research and clinical trials provide hope for the future. In addition, new areas of science may provide revolutionary insights into the drivers of inherited disease and adaptation to drug resistance. Whether immunotherapy will play a prominent role in treatment is still under investigation, as well as the origin of cancer stem cells. This issue will highlight some of the clinical and research advances that sustain hope.
Dr. Mandi Murph
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Epithelial ovarian
- fallopian tube or primary peritoneal Cancer
- COVID-19’s impact on treatment
- Genetic risk correlation – germline or BRCA1/2 somatic mutation testing
- Platinum-based chemotherapy and DNA repair mechanisms
- PARP inhibitors and the DNA damage response
- High- versus low-grade serous carcinoma
- Circulating biomarkers in recurrence detection
- Emerging topics: stem cells, immunotherapy, and non-coding RNAs